Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Apellis Pharmaceuticals Inc (NQ: APLS ) 29.85 -0.74 (-2.42%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Apellis Pharmaceuticals Inc < Previous 1 2 3 4 5 6 7 8 9 ... 16 17 Next > Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 05, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 02, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference December 28, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire 14 Analysts Have This to Say About Apellis Pharmaceuticals December 05, 2023 Via Benzinga Why Is Apellis Pharmaceuticals Stock Trading Lower Today? November 06, 2023 Shares of Apellis Pharmaceuticals Inc (NASDAQ: APLS) declined following a Via Benzinga 21 Analysts Have This to Say About Apellis Pharmaceuticals November 02, 2023 Via Benzinga 10 Health Care Stocks With Whale Alerts In Today's Session December 25, 2023 Via Benzinga Karuna Therapeutics Jumps Following Takeover By Bristol Myers, Joins Rocket Lab USA, Altair Engineering And Other Big Stocks Moving Higher On Friday December 22, 2023 U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of Karuna Therapeutics, Inc. (NASDAQ: KRTX) rose sharply during Friday’s session following acquisition... Via Benzinga Topics Stocks Exposures US Equities Why Is Complement-Mediated Focused Annexon Stock Trading Higher Today? December 21, 2023 On Wednesday, Annexon Inc (NASDAQ: ANNX) reported results from the Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) healthy volunteer study of ANX1502 that targets the active form... Via Benzinga Micron Technology To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Friday December 15, 2023 Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Via Benzinga US Stocks Eye 7-Day Winning Streak As Mortgage Rates Fall Below 7%, Yields Tumble: What's Driving Markets Thursday? December 14, 2023 It’s shaping up to be a positive Thursday on Wall Street, with risk sentiment remaining robust after the Federal Reserve effectively opened the door to rate cuts in 2024. Via Benzinga Topics Economy Exposures Interest Rates 12 Health Care Stocks Moving In Thursday's Intraday Session December 14, 2023 Via Benzinga Why Is Apellis Pharmaceuticals Stock Trading Lower Today? December 14, 2023 Apellis Pharmaceuticals Inc (NASDAQ: APLS) announced an update on the ongoing review of its marketing application for intravitreal pegcetacoplan for geographic atrophy (GA) secondary to age-related... Via Benzinga Apellis Crashes As Likely European Rejection Looms For Eye Drug Syfovre December 14, 2023 The treatment, Syfovre, has faced numerous safety concerns in the U.S., where it's approved. Via Investor's Business Daily Why Amtech Systems Shares Are Trading Higher By Over 30%? Here Are Other Stocks Moving In Thursday's Mid-Day Session December 14, 2023 Shares of Amtech Systems, Inc. (NASDAQ: ASYS) shares fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter sales results and issued first-quarter sales... Via Benzinga 12 Health Care Stocks Moving In Thursday's Pre-Market Session December 14, 2023 Via Benzinga Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union December 14, 2023 Conference call today at 8:30 a.m. ET From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session December 11, 2023 Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the... Via Benzinga Coinbase, Riot Platforms, Marathon Digital And Other Big Stocks Moving Lower On Monday December 11, 2023 U.S. stocks traded mostly mixed, with the Dow Jones index gaining more than 100 points on Monday. Here are some other big stocks recording losses in today’s session. Via Benzinga Topics Stocks Exposures US Equities EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting December 11, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 06, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Apellis Pharmaceuticals Upgraded To Buy: Analyst Sees Potential In Syfovre's Strong Launch December 05, 2023 BofA Securities analyst Tazeen Ahmad upgraded Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) to Buy from Neutral, Via Benzinga Block To Rally Around 54%? Here Are 10 Top Analyst Forecasts For Tuesday December 05, 2023 Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Via Benzinga Magnificent 7 Take Center Stage In Hedge Fund Portfolios: Analysts Warn Of Extreme Concentration November 21, 2023 Hedge fund portfolios are intensifying their focus on technology stocks, with holdings in mega-cap tech reaching record levels. Via Benzinga Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference November 21, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire NASDAQ:APLS Long Term Investor Notice: Investigation of Potential Wrongdoing at Apellis Pharmaceuticals, Inc. November 14, 2023 San Diego, CA -- (SBWIRE) -- 11/14/2023 -- Certain directors of Apellis Pharmaceuticals, Inc. are under investigation on behalf of current long-term investors in shares of Apellis Pharmaceuticals, Inc.... Via SBWire Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 06, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA) November 04, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire APELLIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Apellis Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm November 02, 2023 From Bragar Eagel & Squire Via GlobeNewswire Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results November 01, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire < Previous 1 2 3 4 5 6 7 8 9 ... 16 17 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.